risks related to our common stock our stock price is extremely volatile . the trading price of our common stock has been extremely volatile and may continue to be volatile in the future . many factors could have an impact on our stock price , including fluctuations in our or our competitors 2019 operating results , clinical trial results or adverse events associated with our products , product development by us or our competitors , changes in laws , including healthcare , tax or intellectual property laws , intellectual property developments , changes in reimbursement or drug pricing , the existence or outcome of litigation or government proceedings , including the sec/doj investigation , failure to resolve , delays in resolving or other developments with respect to the issues raised in the warning letter , acquisitions or other strategic transactions , and the perceptions of our investors that we are not performing or meeting expectations . the trading price of the common stock of many biopharmaceutical companies , including ours , has experienced extreme price and volume fluctuations , which have at times been unrelated to the operating performance of the companies whose stocks were affected . anti-takeover provisions in our charter and bylaws and under delaware law could make a third-party acquisition of us difficult and may frustrate any attempt to remove or replace our current management . our corporate charter and by-law provisions may discourage certain types of transactions involving an actual or potential change of control that might be beneficial to us or our stockholders . our bylaws provide that special meetings of our stockholders may be called only by the chairman of the board , the president , the secretary , or a majority of the board of directors , or upon the written request of stockholders who together own of record 25% ( 25 % ) of the outstanding stock of all classes entitled to vote at such meeting . our bylaws also specify that the authorized number of directors may be changed only by resolution of the board of directors . our charter does not include a provision for cumulative voting for directors , which may have enabled a minority stockholder holding a sufficient percentage of a class of shares to elect one or more directors . under our charter , our board of directors has the authority , without further action by stockholders , to designate up to 5 shares of preferred stock in one or more series . the rights of the holders of common stock will be subject to , and may be adversely affected by , the rights of the holders of any class or series of preferred stock that may be issued in the future . because we are a delaware corporation , the anti-takeover provisions of delaware law could make it more difficult for a third party to acquire control of us , even if the change in control would be beneficial to stockholders . we are subject to the provisions of section 203 of the delaware general laws , which prohibits a person who owns in excess of 15% ( 15 % ) of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% ( 15 % ) of our outstanding voting stock , unless the merger or combination is approved in a prescribed manner . item 1b . unresolved staff comments . item 2 . properties . we conduct our primary operations at the owned and leased facilities described below . location operations conducted approximate square feet expiration new haven , connecticut corporate headquarters and executive , sales , research and development offices 514000 2030 dublin , ireland global supply chain , distribution , and administration offices 160000 owned .

operations conducted: new haven connecticut: corporate headquarters and executive sales research and development offices
dublin ireland: global supply chain distribution and administration offices
athlone ireland: commercial research and development manufacturing
lexington massachusetts: research and development offices
bogart georgia: commercial research and development manufacturing
smithfield rhode island: commercial research and development manufacturing
zurich switzerland: regional executive and sales offices
approximatesquare feet: new haven connecticut: 514000
dublin ireland: 160000
athlone ireland: 80000
lexington massachusetts: 81000
bogart georgia: 70000
smithfield rhode island: 67000
zurich switzerland: 69000
leaseexpirationdates: new haven connecticut: 2030
dublin ireland: owned
athlone ireland: owned
lexington massachusetts: 2019
bogart georgia: owned
smithfield rhode island: owned
zurich switzerland: 2025

we believe that our administrative office space is adequate to meet our needs for the foreseeable future . we also believe that our research and development facilities and our manufacturing facilities , together with third party manufacturing facilities , will be adequate for our on-going activities . in addition to the locations above , we also lease space in other u.s . locations and in foreign countries to support our operations as a global organization. .

Questions:
how many square feet are in new haven?
how many square feet are in lexington?
what is the sum?
what is the total sum including square feet in zurich?

Answers:
514000
81000
595000
664000